methyl [N-(N'-tert-butoxycarbonyl)-sulfamoyl]-β-alaninate | 1133725-37-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl [N-(N'-tert-butoxycarbonyl)-sulfamoyl]-β-alaninate
• 英文别名: Methyl 3-[(2-methylpropan-2-yl)oxycarbonylsulfamoylamino]propanoate
• CAS: 1133725-37-7
• 化学式: C₉H₁₈N₂O₆S
• 分子量: 282.318
• InChiKey: ZIVVGHLAWCEUJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl [N-(N'-tert-butoxycarbonyl)-sulfamoyl]-β-alaninate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  [FR] COMPOSÉS À CYCLES CONDENSÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES

  摘要：

  这份披露涉及到式(I)的融合环化合物和/或其药学上可接受的盐，包括式(I)的融合环化合物和/或其药学上可接受的盐的药物组合物，其制备方法，以及在调节吲哚胺2,3-二氧化酶(IDO)和/或色氨酸2,3-二氧化酶(TDO)活性中的应用。这份披露还提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫疾病。

  公开号：

  WO2016131380A1
• 作为产物：
  描述：

  3-氨基丙酸甲酯盐酸盐 、 N-(叔丁氧基羰基)磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以1.62 g的产率得到methyl [N-(N'-tert-butoxycarbonyl)-sulfamoyl]-β-alaninate
  参考文献：
  名称：

  [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  [FR] COMPOSÉS À CYCLES CONDENSÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES

  摘要：

  这份披露涉及到式(I)的融合环化合物和/或其药学上可接受的盐，包括式(I)的融合环化合物和/或其药学上可接受的盐的药物组合物，其制备方法，以及在调节吲哚胺2,3-二氧化酶(IDO)和/或色氨酸2,3-二氧化酶(TDO)活性中的应用。这份披露还提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫疾病。

  公开号：

  WO2016131380A1

文献信息

• Fused-ring compounds, pharmaceutical composition and uses thereof
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US10202388B2

  公开（公告）日：2019-02-12

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  本公开涉及一种式(I)的熔环化合物和/或其药学上可接受的盐、一种包含式(I)的熔环化合物和/或其药学上可接受的盐的药物组合物、其制备方法以及其在调节吲哚胺2，3-二氧化酶(IDO)和/或色氨酸2，3-二氧化酶(TDO)活性中的用途。本公开进一步提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫性疾病。
• Synthesis and Anticonvulsant Activity of Amino Acid-Derived Sulfamides
  作者：Luciana Gavernet、Juan E. Elvira、Gisela A. Samaja、Valentina Pastore、Mariana Sella Cravero、Andrea Enrique、Guillermina Estiu、Luis E. Bruno-Blanch

  DOI：10.1021/jm800764p

  日期：2009.3.26

  Sulfamides are promising functions for the design of new antiepileptic drugs (Bioorg. Med. Chem. 2007, 15, 1556-1567; 5604-5614). Following previous research in this line, a set of amino acid-derived sulfamides has been designed, synthesized, and tested as new anticonvulsant compounds. The experimental data confirmed the ability of some of the structures to suppress the convulsions originated by the electrical seizure (MES test) at low doses (100 mg/kg).
• Inhibition pattern of sulfamide-related compounds in binding to carbonic anhydrase isoforms I, II, VII, XII and XIV
  作者：Luciana Gavernet、José L. Gonzalez Funes、Pablo H. Palestro、Luis E. Bruno Blanch、Guillermina L. Estiu、Alfonso Maresca、Ivana Barrios、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2012.10.048

  日期：2013.3

  A set of sulfamides and sulfamates were synthesized and tested against several isoforms of carbonic anhydrase: CA I, CA II, CA VII, CA XII and CA XIV. The biological assays showed a broad range of inhibitory activity, and interesting results were found for several compounds in terms of activity (K-i < 1 mu m) and selectivity: some aromatic sulfamides are active against CA I, CA II and/or CA VII; while they are less active in CA XII and CA XIV. On the other hand, bulky sulfamides are selective to CA VII. To understand the origin of the different inhibitory activity against each isozyme we used molecular modeling techniques such as docking and molecular dynamic simulations. (C) 2012 Elsevier Ltd. All rights reserved.
• FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US20180022752A1

  公开（公告）日：2018-01-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.
• [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF<br/>[FR] COMPOSÉS À CYCLES CONDENSÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2016131380A1

  公开（公告）日：2016-08-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  这份披露涉及到式(I)的融合环化合物和/或其药学上可接受的盐，包括式(I)的融合环化合物和/或其药学上可接受的盐的药物组合物，其制备方法，以及在调节吲哚胺2,3-二氧化酶(IDO)和/或色氨酸2,3-二氧化酶(TDO)活性中的应用。这份披露还提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫疾病。